Boston Scientific’s stock climbs on Q3 sales and earnings beat
Boston Scientific’s BSX net income was $469 million, or 32 cents a share, down from $505 million, or 34 cents a share, in the same period last year. On an adjusted basis, Boston Scientific reported earnings of 63 cents a share, above the FactSet consensus of 59 cents a share.
Boston Scientific (BSX) shares fell 5% following news that the company has paused a study for its FARAPULSE PFA system due to ...
On Wednesday, Boston Scientific Corporation (NYSE:BSX) reported third-quarter revenues of $4.21 billion, beating the ...
RBC Capital raised the firm’s price target on Boston Scientific (BSX) to $98 from $95 and keeps an Outperform rating on the shares. The ...
The med-tech company with approximately 9,400 employees in Minnesota posted profit and sales that beat Wall Street’s ...
17h
Good morning, Boston. Here are the five things you need to know in local business news to start your busy Thursday.
Boston Scientific's AVANT GUARD trial evaluates the FARAPULSE PFA System for treating persistent atrial fibrillation, pausing ...
The company said, “The company estimates net sales growth for the fourth quarter of 2024, versus the prior year period, to be in a range of approximately 16.5 to 18.5 percent on a reported basis, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback